Weiss Ratings has once again assigned RxSight a “sell (E+)” rating. Another research analyst, Wall Street Zen, similarly adjusted its stance from “hold” to “sell,” indicating a continued sense of caution around RxSight’s stock.

Illinois Tool Works has been underperforming the Dow Jones Industrial Average over the past year, prompting caution among market watchers. This article examines the stock’s lagging performance and the reservations analysts share about its future.